Pictet Group

Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.

Chainalysis Inc. is a blockchain analysis company that specializes in anti-money laundering software tailored for businesses involved with Bitcoin and other cryptocurrencies. Founded in 2014 and headquartered in New York, the company also has offices in Copenhagen, Tokyo, and Singapore. Its product suite includes REACTOR, an interactive investigation tool that identifies offenders and visualizes data, and a real-time API that provides risk scoring based on the source and destination of funds. Chainalysis also produces activity monitoring reports and due diligence tools to help financial institutions understand the risks associated with cryptocurrency activities and to estimate potential criminal revenues. Additionally, the company offers web-based investigation tools to detect cyber-criminals and track extortion payments, thereby enhancing security for government agencies, banks, exchanges, and cryptocurrency businesses.

Red Date Technology one of the four founding members of the Blockchain-based Service Network (BSN).

Cellarity Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing medicines by analyzing cell behaviors. Established in 2017, it utilizes a proprietary platform that digitizes molecular information within cells, shedding light on their functions in both health and disease. By employing advanced single-cell technologies and machine learning algorithms, Cellarity's platform quantifies and elucidates cellular behaviors, enabling a deeper understanding of the complex networks that govern these processes. This innovative approach aims to enhance the efficiency and success rate of drug discovery, allowing for more effective targeting of diseases at the cellular and molecular levels.

NetGuardians SA is a software company based in Yverdon-les-Bains, Switzerland, specializing in mitigation and risk assurance solutions for the banking and financial services sectors. Founded in 2007, the company utilizes big data, user behavior analysis, and transaction analytics to help financial institutions combat various types of fraud, including mobile banking and identity theft. Its key products include FraudGuardian, which addresses specific fraud challenges with predefined controls for continuous auditing, and RiskGuardian, a compliance automation tool that offers templates for regulations, automated controls, and reporting capabilities. Serving CIOs, CISOs, internal auditors, and compliance professionals across Europe, the Middle East, Asia, and Africa, NetGuardians provides its solutions through resellers, ensuring adaptability for various fields of activity. The company also maintains offices in Nairobi, Warsaw, and Singapore.

SOPHiA GENETICS combines deep expertise in life sciences and medical disciplines with mathematical capabilities in data computing. The company aims to bring data analytics solutions to the market, to support healthcare professionals by maximizing the power of data-driven medicine. It achieves this mission through the adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition, and machine learning. This enables SOPHiA to provide equal benefits to all users, unite experts in a gold standard health-tech platform, and motivate expert knowledge sharing for a sustainable impact on future patients. It contributes to making the global healthcare system more sustainable. By helping healthcare professionals leverage their expertise and work together as a community, patients can receive equal access to better diagnoses and treatments. It combines the first two pillars of data-driven medicine, genomics, and radionics, the company ensures that the data used to help patients. Founded by Jurgi Camblong, Lars Steinmetz, and Pierre Hutter, SOPHiA GENETICS was incorporated in 2011. It has offices in Boston, Massachusetts, Switzerland, and France.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2010. It specializes in the development of therapeutics and vaccines utilizing messenger RNA technology, which instructs cells to produce proteins essential for various biological functions. The company's extensive pipeline includes 40 mRNA development candidates targeting a range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Moderna gained significant recognition with its COVID-19 vaccine, which was authorized for use in the United States in December 2020. The company maintains strategic partnerships with organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation, enhancing its research capabilities and manufacturing processes. Additionally, it has research collaborations with esteemed institutions like Harvard University.

Athena Art Finance is a specialty finance company based in New York that provides loans secured by high-value fine art collections. Its services cater to the global art market, focusing on debt origination, portfolio management, and the distribution of art-backed credit risk. The company operates as a subsidiary of YieldStreet and is financially supported by private equity sponsors, including The Carlyle Group and Pictet Group. Through its platform, Athena Art Finance aims to offer tailored lending solutions to art collectors and investors.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.

NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.

NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.

Bluetrain.com is now accepting applications for its Pilot Program. They have limited space available for our first phase, but will try to accomodate additional participants as quickly as They can.

A provider of natural language interface products for the Internet